The BDNF Val68Met polymorphism causes a sex specific alcohol preference over social interaction and also acute tolerance to the anxiolytic effects of alcohol, a phenotype driven by malfunction of BDNF in the ventral hippocampus of male mice.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 06 12 2022
accepted: 19 12 2022
pubmed: 10 1 2023
medline: 31 1 2023
entrez: 9 1 2023
Statut: ppublish

Résumé

The brain-derived neurotrophic factor (BDNF) Valine 66 to Methionine human polymorphism results in impaired activity-dependent BDNF release and has been linked to psychiatric disorders including depression and anxiety. We previously showed that male knock-in mice carrying the mouse Methionine homolog (Met68BDNF) exhibit excessive and compulsive alcohol drinking behaviors as compared to the wild-type Val68BDNF mice. Here, we set out to determine the potential mechanism for the heightened and compulsive alcohol drinking phenotypes detected in Met68BDNF mice. We found that male, but not female Met68BDNF mice exhibit social anxiety-like behaviors. We further show that male Met68BDNF mice exhibit a preference for alcohol over social interaction. In contrast, alcohol place preference without an alternative social reward, is similar in male Met68BDNF and Val68BDNF mice. Since the Met68BDNF mice show social anxiety phenotypes, we tested whether alcohol reliefs anxiety similarly in Met68BDNF and Val68BDNF mice and found that male, but not female Met68BDNF mice are insensitive to the acute anxiolytic action of alcohol. Finally, we show that this acute tolerance to alcohol-dependent anxiolysis can be restored by overexpressing wild-type Val68BDNF in the ventral hippocampus (vHC) of Met68BDNF mice. Together, our results suggest that excessive alcohol drinking in the Met68BDNF may be attributed, in part, to heighted social anxiety and a lack of alcohol-dependent anxiolysis, a phenotype that is associated with malfunction of BDNF signaling in the vHC of male Met68BDNF mice.

Sections du résumé

BACKGROUND BACKGROUND
The brain-derived neurotrophic factor (BDNF) Valine 66 to Methionine human polymorphism results in impaired activity-dependent BDNF release and has been linked to psychiatric disorders including depression and anxiety. We previously showed that male knock-in mice carrying the mouse Methionine homolog (Met68BDNF) exhibit excessive and compulsive alcohol drinking behaviors as compared to the wild-type Val68BDNF mice.
OBJECTIVE OBJECTIVE
Here, we set out to determine the potential mechanism for the heightened and compulsive alcohol drinking phenotypes detected in Met68BDNF mice.
RESULTS RESULTS
We found that male, but not female Met68BDNF mice exhibit social anxiety-like behaviors. We further show that male Met68BDNF mice exhibit a preference for alcohol over social interaction. In contrast, alcohol place preference without an alternative social reward, is similar in male Met68BDNF and Val68BDNF mice. Since the Met68BDNF mice show social anxiety phenotypes, we tested whether alcohol reliefs anxiety similarly in Met68BDNF and Val68BDNF mice and found that male, but not female Met68BDNF mice are insensitive to the acute anxiolytic action of alcohol. Finally, we show that this acute tolerance to alcohol-dependent anxiolysis can be restored by overexpressing wild-type Val68BDNF in the ventral hippocampus (vHC) of Met68BDNF mice.
CONCLUSIONS CONCLUSIONS
Together, our results suggest that excessive alcohol drinking in the Met68BDNF may be attributed, in part, to heighted social anxiety and a lack of alcohol-dependent anxiolysis, a phenotype that is associated with malfunction of BDNF signaling in the vHC of male Met68BDNF mice.

Identifiants

pubmed: 36622381
doi: 10.1007/s00213-022-06305-3
pii: 10.1007/s00213-022-06305-3
pmc: PMC9879818
doi:

Substances chimiques

Anti-Anxiety Agents 0
Brain-Derived Neurotrophic Factor 0
Ethanol 3K9958V90M
Methionine AE28F7PNPL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

303-317

Subventions

Organisme : NIAAA NIH HHS
ID : R37AA01684
Pays : United States
Organisme : NIH HHS
ID : F32AA028422
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Pharmacol Rev. 2016 Apr;68(2):242-63
pubmed: 26772794
Arch Gen Psychiatry. 1985 Apr;42(4):375-9
pubmed: 3977555
Neuron. 2013 Mar 6;77(5):955-68
pubmed: 23473324
Nat Protoc. 2007;2(2):322-8
pubmed: 17406592
Anxiety Stress Coping. 2016 Jul;29(4):432-46
pubmed: 26235528
Curr Opin Neurobiol. 2018 Apr;49:132-140
pubmed: 29518698
Acta Biochim Pol. 2013;60(2):163-6
pubmed: 23745178
Psychol Addict Behav. 2010 Dec;24(4):640-8
pubmed: 21198225
Biotechnol J. 2012 Jan;7(1):133-47
pubmed: 22076863
Nord J Psychiatry. 2018 Feb;72(2):130-136
pubmed: 29117747
Depress Anxiety. 2018 Sep;35(9):851-860
pubmed: 29999576
Mol Psychiatry. 2010 Mar;15(3):260-71
pubmed: 18852698
Alcohol Clin Exp Res. 2009 Apr;33(4):693-702
pubmed: 19170664
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10825-30
pubmed: 12149439
Curr Opin Neurobiol. 2018 Dec;53:120-130
pubmed: 30059820
Psychoneuroendocrinology. 2011 Nov;36(10):1562-9
pubmed: 21596481
Nat Neurosci. 2018 Dec;21(12):1656-1669
pubmed: 30482948
Neuropsychopharmacology. 2017 Jul;42(8):1715-1728
pubmed: 28294135
iScience. 2020 Mar 27;23(3):100894
pubmed: 32092698
Neuroscience. 2019 Feb 1;398:144-157
pubmed: 30481568
Neuron. 2018 Feb 7;97(3):670-683.e6
pubmed: 29397273
Curr Top Behav Neurosci. 2022 May 24;:
pubmed: 35604571
Mol Psychiatry. 2021 Mar;26(3):955-973
pubmed: 30992540
Biol Psychiatry. 2016 Mar 15;79(6):463-73
pubmed: 26204799
Drug Alcohol Depend. 2009 Feb 1;100(1-2):128-37
pubmed: 19022589
Neuron. 2016 Feb 17;89(4):857-66
pubmed: 26853301
Neurosci Biobehav Rev. 2022 Jan;132:730-756
pubmed: 34839930
Alcohol. 2013 Jun;47(4):271-4
pubmed: 23582695
Neuroimage. 2016 Jan 1;124(Pt B):1149-1154
pubmed: 25937488
Acta Biochim Pol. 1999;46(3):591-9
pubmed: 10698267
Neuroscientist. 2012 Oct;18(5):439-51
pubmed: 22367929
Neuron. 2010 Jan 28;65(2):257-69
pubmed: 20152131
Science. 2006 Oct 6;314(5796):140-3
pubmed: 17023662
J Neurosci. 2004 May 5;24(18):4401-11
pubmed: 15128854
J Neurosci. 2009 Oct 28;29(43):13494-502
pubmed: 19864562
iScience. 2022 Jan 05;25(2):103735
pubmed: 35098101
J Neurosci. 2014 Jan 8;34(2):586-95
pubmed: 24403157
Addict Behav. 2020 May;104:106284
pubmed: 31927489
Nat Commun. 2020 May 6;11(1):2221
pubmed: 32376858
Pharmacol Biochem Behav. 2021 May;204:173155
pubmed: 33631255
BMC Psychiatry. 2014 Mar 26;14:89
pubmed: 24670230
J Neurosci. 2005 Jun 29;25(26):6156-66
pubmed: 15987945
Genes Brain Behav. 2004 Oct;3(5):287-302
pubmed: 15344922
J Neurosci. 2016 Mar 16;36(11):3281-94
pubmed: 26985037
Eur Arch Psychiatry Clin Neurosci. 2018 Apr;268(3):219-229
pubmed: 28439723
Alcohol. 2015 Mar;49(2):103-10
pubmed: 25650137
Harv Rev Psychiatry. 1997 Jan-Feb;4(5):231-44
pubmed: 9385000
Cell. 2022 Jan 6;185(1):62-76
pubmed: 34963057
Addict Behav. 2017 Jan;64:185-193
pubmed: 27619010
Eur J Neurosci. 2013 Feb;37(4):607-12
pubmed: 23189980
Cell. 2022 Feb 17;185(4):654-671.e22
pubmed: 35065713
Alcohol Clin Exp Res. 2003 Nov;27(11):1736-42
pubmed: 14634488
Am J Psychiatry. 1985 Nov;142(11):1259-64
pubmed: 3904487
Sci Rep. 2018 Jul 3;8(1):10040
pubmed: 29968802
Lancet Psychiatry. 2019 Dec;6(12):1068-1080
pubmed: 31630984
Mol Psychiatry. 2015 Aug;20(8):916-30
pubmed: 25824305
Behav Brain Funct. 2018 Mar 19;14(1):7
pubmed: 29554926
Alcohol Clin Exp Res. 2004 Nov;28(11):1609-12
pubmed: 15547445
Science. 2016 Sep 30;353(6307):1536-1541
pubmed: 27708103
Dev Cogn Neurosci. 2018 Nov;34:34-41
pubmed: 29909248
Pharmacol Rep. 2010 Sep-Oct;62(5):938-41
pubmed: 21098877
Cell. 2003 Jan 24;112(2):257-69
pubmed: 12553913
Alcohol Clin Exp Res. 2019 Oct;43(10):2232-2241
pubmed: 31454095
Depress Anxiety. 2008;25(12):1028-37
pubmed: 18781667
Front Cell Neurosci. 2019 Apr 09;13:135
pubmed: 31024262
J Vis Exp. 2011 Feb 25;(48):
pubmed: 21403628
Neuron. 2017 Sep 27;96(1):145-159.e8
pubmed: 28890345
Science. 2015 May 1;348(6234):560-3
pubmed: 25931556
Neuropsychopharmacology. 2021 Jan;46(2):334-342
pubmed: 32417851

Auteurs

Jeffrey J Moffat (JJ)

Department of Neurology, University of California, 675 Nelson Rising Lane, BOX 0663, San Francisco, CA, 94143-0663, USA.

Samuel A Sakhai (SA)

Department of Neurology, University of California, 675 Nelson Rising Lane, BOX 0663, San Francisco, CA, 94143-0663, USA.

Zachary W Hoisington (ZW)

Department of Neurology, University of California, 675 Nelson Rising Lane, BOX 0663, San Francisco, CA, 94143-0663, USA.

Yann Ehinger (Y)

Department of Neurology, University of California, 675 Nelson Rising Lane, BOX 0663, San Francisco, CA, 94143-0663, USA.

Dorit Ron (D)

Department of Neurology, University of California, 675 Nelson Rising Lane, BOX 0663, San Francisco, CA, 94143-0663, USA. dorit.ron@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH